What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2026-06-12 compared with 2026-03-12 · 32 added, 9 removed, 22 unchanged (65% of the section changed)

Other Information

fiscal quarter ended January 31, 2026, no director or officer of the Company adopted

or terminated

a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in

Item 408(a) of Regulation S-K.

The following exhibits are filed herewith and this

list constitutes the exhibit index.

During the quarter ended April 30, 2026, no director

or officer adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”

as each term is defined in Item 408(a) of Regulation S-K.

The following exhibits are filed herewith and this list constitutes

the exhibit index.

Exhibit Number

Exhibit Description

Technology and Sub-License Agreement between Odyssey Health, Inc.

and NeuRX Health, Inc (incorporated by reference to Exhibit

10.1 to Form 8-K filed with the SEC on October 17, 2025).

Amendment No.

1, dated April 21, 2026, to the Master Technology and Sub-License Agreement dated October 14, 2025 (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on April 24, 2026).

NeuRX Health, Inc.

Revocation Letter dated May 6, 2026 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 11, 2026)

of Amendment No.

12 dated January 30, 2026, to Convertible Promissory Note with Directors and Officers, dated December 21, 2021 and

December 22, 2021 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on February 3, 2026)

Amendment No.

11 dated January 30, 2026 to Convertible Promissory Note with LGH Investments, LLC dated April 5, 2021 (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on February 3, 2025).

5 dated January 30, 2026, to the Promissory Note with accredited investor Jonathan Lutz, dated February 13, 2024 (incorporated

by reference to Exhibit 10.3 to Form 8-K filed with the SEC on February 3, 2025)

2 dated February 2, 2026 and effective January 30, 2026, to the Promissory Note with accredited investor Peter J.

dated August 14, 2024 (incorporated by reference to Exhibit 10.4 to Form 8-K filed with the SEC on February 3, 2026)

Amendment No.

12 dated May 18, 2026 to Convertible Promissory Note with LGH Investments, LLC dated April 5, 2021 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 26, 2026).

Amendment No.

6 dated October 9, 2025 to Promissory Note issued December 13, 2022 with Mast Hill Fund, L.P (incorporated by reference to Exhibit 10.

1 to Form 8-K filed with the SEC on October 10, 2025)

Amendment No.

7 dated June 9, 2026 to Promissory Note issued December 13, 2022 with Mast Hill Fund, L.P.

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934

9 unchanged sentences

Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101).

Pursuant to the requirements of Section 13 or 15(d)

of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto

duly authorized, as of March 11, 2026.

** Filed herewith

Pursuant to the requirements of Section 13

or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned,

thereunto duly authorized, as of June 12, 2026.

ODYSSEY HEALTH, INC.

7 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information